Evidence map›Paper›PMID 38077239›Full record

ArticleNeuropsychiatric disease and treatment2023

Ferulic Acid Activates SIRT1-Mediated Ferroptosis Signaling Pathway to Improve Cognition Dysfunction in Wilson's Disease.

Xie Wang, Nan Shao, Xiaoyan Zhang, Hong Chen, Ze Chang, Daojun Xie, Juan Zhang

Open access · goldAbstract read
In one paragraph

Article in Neuropsychiatric disease and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. In defence of ferroptosis.Signal transduction and targeted therapy · 2025
    Review
  10. Review
  11. Potential role of SIRT1 in cell ferroptosis.Frontiers in cell and developmental biology · 2025
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xie Wang *The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei, 230038, People's Republic of China.ORCID 0009-0003-6627-9702
Nan Shao *The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei, 230038, People's Republic of China.
Xiaoyan Zhang *The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei, 230038, People's Republic of China.ORCID 0009-0002-9650-3800
Hong Chen *The First Clinical Medical College of Anhui University of Chinese Medicine, Hefei, 230038, People's Republic of China.ORCID 0000-0002-9026-9112
Ze Chang *Xiyuan Hospital of China Academy of Traditional Chinese Medicine, Beijing, 100091, People's Republic of China.ORCID 0000-0001-9954-1584
Daojun XieDepartment of Neurology, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, People's Republic of China.
Juan ZhangDepartment of Neurology, the First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, 230031, People's Republic of China.
Anhui University of Traditional Chinese Medicine · CNXiyuan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Wilson's disease (WD), an autosomal recessive genetic disease, is characterized by copper metabolism disorder. WD patients may have a series of cognitive deficits in terms of neurological symptoms. Ferroptosis (FPT), a type of programmed cell death, is involved in the pathological progression of various cognitive disorders, and silent information regulator 1 (SIRT1) is considered to be a key factor in FPT. Ferulic acid (FA) is a traditional Chinese medicine monomer, with a remarkable effect in the clinical treatment of cognitive impairment-related disease. However, its intrinsic effect on FPT is still unclear. This study aims to investigate the protective effect of FA on cognitive impairment in animal and cell models of WD, and whether the pharmacological mechanism is related to the SIRT1-mediated FPT signaling pathway. Methods: Copper-loaded WD rats and PC12 cells WD were used as models of cognitive dysfunction in vivo and in vitro, respectively. Morris Water Maze (MWM) was used to evaluate the spatial exploration and memory abilities of rats. HE staining was used to observe neuronal damage in the CA1 region of the rat hippocampus. Immunofluorescence (IF) was used to detect the expression of GPX4 protein. Transmission electron microscopy (TEM) was used to observe the ultrastructure of neurons. The levels of Fe2+, MDA, SOD, GSH, 4HNE, and ROS were detected. Western blot and qRT-PCR were used to detect the protein and mRNA levels of SIRT1, Nrf2, SCL7A11, and GPX4. Results: In the WD copper-loaded model rats, MWM, TEM, and IF results showed that FA could promote the repair of learning and memory function, improve the morphological damage to hippocampal neurons, and maintain mitochondria integrity. In the PC12 cell experiment, the MTT method showed that FA increased the viability of copper-overloaded cell models. Western blot and qRT-PCR results confirmed that FA significantly increased the expression of proteins and mRNA in SIRT1, Nrf2, SCL7A11, and GPX4. In addition, FA reversed the expression of oxidative stress-related indicators, including MDA, SOD, GSH, 4HNE, and ROS. Conclusion: FA alleviates hippocampal neuronal injury by activating SIRT1-mediated FPT, providing a valuable candidate for traditional Chinese medicine monomer for the clinical therapeutics of WD cognitive impairment.

Indexed as

ferroptosisferulic acidPC12 cellsSIRT1Wilson’s disease cognitive impairment

Identifiers

PMID38077239
PMCPMC10710261
OpenAlexW4389341664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.